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Huntington’s disease (HD) is a currently incurable neurodegenerative condition caused by an 
abnormally expanded polyglutamine tract in huntingtin (HTT). We identified novel modifiers of 
mutant HTT toxicity by performing a large-scale “druggable genome” siRNA screen in human 
cultured cells, followed by hit validation in Drosophila. We focused on glutaminyl cyclase 
(QPCT), which had one of the strongest effects on mutant HTT-induced toxicity and aggregation 
in the cell-based siRNA screen, and which also rescued these phenotypes in Drosophila. We 
found that QPCT inhibition induced the levels of the molecular chaperone alpha B-crystallin and 
reduced the aggregation of diverse proteins. We generated novel QPCT inhibitors using in silico 
methods followed by in vitro screens, which rescued the HD-related phenotypes in cell, 
Drosophila and zebrafish HD models. Our data reveal a novel HD druggable target affecting 
mutant huntingtin aggregation, and provide proof-of-principle for a discovery pipeline from 
druggable genome screen to drug development.
Introduction
Huntington’s disease (HD) is a fatal, currently incurable, late-onset neurodegenerative 
disorder. The disease signs include involuntary and repetitive choreic movements, 
psychological dysfunction and cognitive impairment, which result from progressive 
degeneration of cortical and striatal neurons 12.
HD is caused by the expansion of a CAG repeat tract in exon 1 of the gene encoding 
huntingtin (HTT), which results in an abnormally long polyglutamine stretch in the N-
terminus of the protein 3. Although the mechanisms are not fully understood, it is believed 
that the disease arises from a toxic-gain-of function of the mutant protein 45. A hallmark of 
HD is the presence of intracellular aggregates, which is also a characteristic of the other ten 
polyglutamine-expansion disorders, as well as other neurodegenerative conditions such as 
Parkinson’s or Alzheimer’s disease 6. The role of these aggregates in the disease is not clear, 
although an increasing importance of the oligomeric forms in toxicity is emerging 78 and 
reducing mutant HTT aggregation with strategies such as pharmacological upregulation of 
chaperone function has been pursued as a therapeutic strategy in HD 9. Mutant HTT toxicity 
is believed to be accentuated, or possibly induced, after cleavage events resulting in the 
formation of short N-terminal polyglutamine containing fragments, which can also be 
produced by aberrant splicing 10. Hence, exon 1 models have been frequently used for 
disease modeling.
Here, we combined two approaches to identify modifiers of mutant HTT toxicity by first 
performing a cell-based screen to identify genes that when knocked down could suppress 
mutant HTT-induced toxicity, using a library of 5,623 siRNAs selected according to the 
potential druggability of their targets with small molecules 11. We performed this screen in 
two different HD models. Initially, we screened the effects of siRNAs in a mammalian cell 
line inducibly expressing HTT with an abnormal polyglutamine expansion. In a secondary 
analysis, we validated primary hits in a Drosophila model of HD.
One of the strongest suppressors of mutant HTT toxicity in both mammalian cells and 
Drosophila was an enzyme responsible for the modification of N-terminal residues of 
glutamine or glutamate into an N-terminal 5-oxoproline or pyroglutamate (pE), named 
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glutaminyl cyclase (QPCT).. QPCT not only suppressed mutant HTT induced toxicity but 
also greatly reduced the number of aggregates. This effect is not HTT-specific, since QPCT 
exerted a general effect on aggregation of different aggregate-prone proteins, including other 
proteins containing an expanded polyglutamine or polyalanine tract, which could be 
attributed to increased levels of the chaperone alpha B-crystallin upon QPCT inhibition. 
Furthermore, we designed small molecule modulators of QPCT activity, which effectively 
suppressed mutant HTT aggregation and toxicity in cells, neurons, fly and zebrafish models 
of the disease.
Results
Primary cell screen for suppressors of mutant Htt toxicity
We performed the primary screen using a stable HEK293/T Rex cell line expressing full-
length human HTT bearing 138 polyglutamines (Q138) under the control of a tetracycline-
inducible promoter. We confirmed the expression of HTT(Q138) after inducing the cells 
with doxycycline using antibodies recognizing the N-terminus of human HTT 
(Supplementary Results, Supplementary Fig. 1a and Supplementary Note 1), and 
quantitative RT-PCR using primers spanning different areas of the human HTT cDNA 
(Supplementary Fig. 1b). This cell line had reduced cell viability after expression of mutant 
HTT, which was reverted by treatment with a known reference compound (Y27632) 12 
(Supplementary Fig. 1c), suggesting that this model could be used to identify potential 
modulators of mutant HTT cellular toxicity in a large-scale screen.
For our high-throughput screen, we utilised a strategy consisting of an iterative siRNA 
screen where positive genes were selected after three consecutive rounds to compensate for 
the variability of the assay. We eliminated non-positive siRNAs and added new siRNAs 
targeting the selected genes in consecutive passes. We assessed rescue of cellular toxicity by 
each siRNA by fluorescence microscopy and automated image analysis using three 
independent readouts: 1) number of cell nuclei (#nuclei), 2) apoptotic index and 3) aberrant 
nuclei index, and used rescue indices to express the effect of each individual siRNA for each 
parameter analysed. In an initial screen, we tested 3 independent siRNAs for each of the 
5,623 genes (a total of 16,869 siRNAs), from which we selected 670 primary genes (see 
Supplementary Note 1 for screen assay and criteria selection). As shown in supplementary 
figure 2a, the three readouts were partially redundant, as more than 50% of the 1,000 top 
scoring siRNAs of one rescue index also ranked amongst the top 1,000 siRNAs of at least 
one of the other rescue indices. In supplementary figure 1b, a representation of rescue 
indices obtained in pass 1 shows the relatively large variability of the assay, with non-
targeting negative control siRNAs, negQ and negF, showing a #nuclei rescue indices of 14% 
and 3% respectively, while using siRNA targeting HTT as a positive control rendered a 
mean #nuclei rescue index of 81%.
After 3 consecutive rounds of screening, we selected and 257 genes and ranked these based 
on all three rescue indices, using #nuclei rescue index as a primary criterion (Supplementary 
Data Set 1).
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Secondary RNAi screening in a Drosophila model of HD
To validate the hits obtained in mammalian cells and to focus on targets with potential 
relevance in vivo, we performed a secondary screen in a Drosophila model that expressed a 
construct containing 48 polyglutamines, Q48, that causes eye degeneration when expressed 
using a GMR-GAL4 driver 13. For most genes selected, we studied two UAS-RNAi 
constructs from the Vienna Drosophila RNAi Center (VDRC): a P-element (GD) and a 
phiC31 (KK) construct, the latter of which carries more GAL4-binding sites and should 
therefore express the RNAi more strongly 14. Of the 257 mammalian genes previously 
selected, we detected 133 that had one or more gene orthologs in flies (Supplementary Data 
Set 1 and 2). Of these 133 mammalian genes with fly orthologs, 74 Drosophila genes 
(corresponding to 66 mammalian genes) rescued the Q48-induced eye degeneration with at 
least one RNAi line, while the others showed no obvious or significant effect 
(Supplementary Fig. 3a and 3b and Supplementary Data Sets 1 and 2). We crossed 
suppressor RNAi lines to transgenic flies that expressed EGFP, also driven by the same 
GMR-GAL4 driver. We used EGFP to test whether modifiers affected transgene protein 
synthesis, since Q48 levels can be modified by aggregation or autophagic degradation, 
which do not impact EGFP levels. Two of these fly RNAi lines, targeting orthologs to 
human CTSF and to human ADAM8, ADAM11 and ADAM33, reduced EGFP levels on 
western blots (Supplementary Data Set 2), suggesting a general effect of these genes in 
protein expression, while suppression exerted by the other RNAi lines seemed to be 
polyglutamine-specific.
Functional categorization of mutant HTT modifiers
To gain further insight into the biological relevance of the data generated, we categorized 
the different sets of HD toxicity modulators according to their molecular function. 
Suppressors were enriched for certain classes of proteins such as GPCRs or transporters 
compared to the initial library, while the number of positive kinases in the screen was 
reduced and no cytokines, growth factors or translational regulators were represented. We 
observed similar functional categorizations after selection from the cell and Drosophila 
screen (Supplementary Fig. 4a). An Ingenuity Pathway Analysis (IPA) of the hits obtained 
in the primary screen in cells (Supplementary Table 1a) revealed that the majority of these 
proteins participate in general processes such as GPCR- or cAMP-mediated signalling, but 
also in canonical pathways related to neurodegeneration, such as apoptosis, mitochondrial 
dysfunction, amyloid processing or protein ubiquitination. Importantly, 10 of these proteins 
have been previously related to HD signalling, including subunits of the succinate 
dehydrogenase complex and huntingtin-associated protein 1 (HAP1) (Supplementary Table 
1a). Many of the genes validated in Drosophila (Supplementary Fig. 4b and Supplementary 
Table 1b) are also involved in processes related to neurodegeneration but were enriched in 
mitochondrial metabolic pathways, especially those associated with fatty acid biosynthesis 
and metabolism.
Validation of QPCT in Drosophila
We focused our attention on a gene that had one of the strongest and most consistent effects 
in rescuing mutant HTT-induced toxicity in the cell-based siRNA screen. The gene product 
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has glutaminyl cyclase activity and is named QPCT. Two orthologs have been reported in 
fly 15, Glutaminyl cyclase (QC) and iso Glutaminyl cyclase (isoQC), which show about 39% 
amino acid identity; a third fly ortholog, CG6168, shows expression restricted to male 
accessory glands (www.flyatlas.org) and is not considered further here. RNAi lines targeting 
either QC or isoQC partially rescued eye depigmentation and mediated a significant 
decrease in the number of black spots in flies expressing Q48 (Fig. 1a, 1b and 
Supplementary Fig. 5a) (Data are shown for GD- and KK-RNAi lines in the case of QC, but 
only a KK line was available for isoQC). These effects are likely independent of 
transcription/translation of the Q48, since no change in EGFP protein levels were seen when 
we crossed transgenic flies expressing EGFP driven by the same GMR-GAL4 driver as Q48 
with QC or isoQC RNAi lines (Supplementary Fig. 5b). Thus, QPCT represents an 
interesting candidate for studying in HD.
To further evaluate the benefits of downregulating QPCT on HD, we took advantage of an 
additional Drosophila model of neurodegeneration, HD flies that express exon 1 of HTT 
with 120 polyglutamines, GMR-HTT.Q120 in eye photoreceptors 16. Drosophila 
melanogaster has a compound eye consisting of many ommatidia, each of which is 
composed of 8 photoreceptors, seven of which can be visualized by light microscopy using 
the pseudopupil technique 17. Neurodegeneration results in the loss of visible rhabdomeres 
of each photoreceptor and can be rescued or enhanced by genetic or chemical approaches 18. 
Consistent with our data using the Q48 flies, the loss of visible photoreceptors in transgenic 
flies expressing GMR-HTT.Q120 was partially rescued when they were crossed with RNAi 
lines for either of the two QPCT fly orthologues, QC and isoQC (Fig. 1c). We observed no 
effect on the number of rhabdomeres in QPCT RNAi lines in the absence of GMR-
HTT.Q120. The effects of QPCT knockdown on toxicity correlated with a reduction in HTT 
aggregation, which we assessed in flies expressing GFP-tagged expanded huntingtin exon 1, 
HTTEx1-Q46-eGFP in the eye 19 (Fig. 1d).
QPCT modulates mutant HTT aggregation
To further validate QPCT, we first confirmed the protective effect of its knockdown against 
toxicity and aggregation in HEK293 cells expressing the exon 1 of HTT (from residue 8) 
with a 74 polyglutamine expansion fused at its N-terminal to EGFP (EGFP-HTT(Q74)) 20 
(Fig. 2a, Supplementary fig. 6a and 6b). The QPCT siRNAs used in these experiments as 
well as in the screen do not target QPCT-like, which encodes a paralogous protein that 
catalyzes a similar reaction and shows 51% of sequence identity to QPCT (Supplementary 
Fig. 6b and 6c). We also validated the effect of QPCT knockdown on aggregation in HeLa 
cells (Supplementary Fig. 6d) which, like HEK293 cells, express QPCT 21. We also 
confirmed a decrease in protein aggregation of a construct which expresses full-length HTT 
carrying 138 polyglutamines (similar to the one used in the initial screen) (Supplementary 
Fig. 6e). QPCT siRNA did not have a general anti-apoptotic effect as it did not affect 
caspase 3 activity in response to staurosporine treatment (Supplementary Fig. 6f). Consistent 
with these data, QPCT shRNA reduced EGFP-Q80 (80 glutamines fused to EGFP) 
aggregation in primary cortical neurons (Fig. 2b and Supplementary fig. 6g). We could not 
assess the effect of QPCT knockdown on polyglutamine-mediated toxicity in these neurons, 
where the levels of cell death obtained in this assay were very low, as can be appreciated in 
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fig. 2b. While knocking down QPCT was protective, overexpression of QPCT in HeLa and 
HEK293 cells increased the numbers of apoptotic nuclei and also led to a large 
accumulation of HTT(Q74) aggregates (Fig. 2c and Supplementary Fig. 7a), while QPCT 
did not increase caspase activity upon staurosporine treatment (Supplementary Fig. 7b). The 
effects of QPCT were activity-dependent, since the catalytically inactive E201Q mutant did 
not increase the percentage of cells with HTT(Q74) aggregates (Fig. 2d and Supplementary 
Fig. 7c and 7d).
We measured mRNA levels of QPCT in HD mice and found that its expression was reduced 
when compared to their wild-type littermates, suggesting that QPCT expression may be 
downregulated as a compensatory mechanism (Supplementary Fig. 8) and that raised QPCT 
activity may not be a prerequisite for aggregation.
QPCT catalyzes the modification of N-terminal glutamines or glutamates into a 
pyroglutamate (pE) residue. Although the presence of an extended polyglutamine tract 
makes HTT a potential substrate for QPCT, this enzyme only modifies N-terminal residues, 
suggesting that any modification on mutant HTT would require an N-terminal cleavage to 
reveal a glutamine at the N-terminal that could be cyclated. The formation of a pE residue 
may then affect its stability and propensity to aggregate, a hypothesis that was previously 
suggested 22. This cleavage model in either the polyglutamine tract or HTT exon 1 or GFP is 
unlikely, as QPCT modulated the aggregation of constructs consisting only of isolated 
polyglutamine expansions (Q57 and Q81) fused C-terminal to EGFP (Fig. 2e and 2f), or 
HTT exon 1 with 74 glutamines fused to HA 23 (Supplementary Fig. 9a and 9b), and QPCT 
siRNA also reduced the aggregation of an expansion of 37 alanines 24 (Fig. 2f). QPCT 
appeared to modulate the early stages of mutant HTT oligomerisation, since QPCT 
overexpression increased the amounts of Flag-tagged monomeric mutant HTT that were co-
immunoprecipitated by GFP-tagged mutant HTT (Fig. 2g) 25. Since QPCT did not interact 
with HTT directly by immunoprecipitation (e.g. Fig. 2g), its effect on HTT oligomer 
formation is likely mediated via intermediaries.
Design and characterization of compounds that inhibit QPCT
To target QPCT pharmacologically, we tested a previously described QPCT inhibitor 26, 
which did not rescue the HD phenotype in mammalian cells (Supplementary Fig. 10a and 
10b). While this compound has been effective in Alzheimer disease (AD) models by 
reducing the formation of extracellular pE-Aβ, this may be due to extracellular QPCT 
inhibition 2127. Thus, we reasoned that the failure of this compound was likely due to poor 
cell permeability. In order to generate novel QPCT inhibitors, we employed existing data on 
its structure and known inhibitors to generate three 3D pharmacophore models, two ligand-
based and one structure-based (using the human QPCT X-Ray structure (PDB id: 2AFW)). 
We used these models, along with stringently applied CNS filters and a solubility model 
developed in-house, to select 10,000 compounds from both commercially available 
screening compounds and the SienaBiotech compound library. We screened these molecules 
in a functional assay assessing the conversion of the H-Glu-AMC fluorogenic substrate into 
pyroGlu-AMC, as previously described 28, and selected hits associated with predicted robust 
binding for the hit-to-lead phase. The optimization strategy was based on physicochemical 
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properties and ensemble docking model-driven approaches. The ensemble docking 
methodology 2930 was chosen to take into account the flexibility of human QPCT catalytic 
site and was constructed using both X-Ray structures and protein conformations coming 
from a 100 ns molecular dynamic study of the human QPCT 2AFW X-Ray structure. The 
ensemble docking model was evolved during the project development. Initially, only 4 X-
Ray structures were used (PDB ID: 2AFW, 2AFX, 2AFZ31), then a set of 16 protein 
conformations, selected by clustering of molecular dynamic simulations, were added to 
improve model accuracy. Recently, two more X-Ray structures were added to the model 
(3PBB32 an 3SI033). All the docking calculations were performed using CCDC Gold 
(versions 4 and 5)343536 along with an ad-hoc developed program to rank and select the best 
scored ligand docking pose from the pool of QPCT conformations. Along with the 
biochemical readouts used during this optimization, we included a range of in vitro ADME 
assays, including solubility measurements, a CNS membrane permeability assay (PAMPA-
BBB) 37 and stability in the presence of human CYP3A4, a member of the cytochrome P450 
mixed-function oxidase system, and a key enzyme involved in the metabolism of 
xenobiotics in humans.
We selected a series of compounds on the basis of these properties and validated their 
effects on mutant HTT aggregation and toxicity in cells expressing HTT(Q74)GFP, which 
led to the selection of three of them, SEN177 (1), SEN817 (2) and SEN180 (3) 
(Supplementary note 2, Fig. 3a, Supplementary Fig. 11a). Non-toxic concentrations of these 
compounds caused a dose-dependent reduction in the percentage of cells with aggregates, 
which correlated with a suppression of mutant HTT-induced apoptosis (Fig. 3b, 3c, 3d, 3d 
and Supplementary Fig. 11b). As seen with genetic knockdown experiments, pharmacologic 
inhibition of QPCT using these compounds also reduced aggregation of polyalanines (Fig. 
3d) and did not affect protein levels, as assessed by measuring GFP levels by western 
blotting (Supplementary Fig. 11c) or by metabolic labeling of wild type HTT followed by 
detection of newly synthesized protein in the presence of SEN177 (Supplementary Fig. 
11d). Importantly, the effect of these compounds was blocked when QPCT expression was 
suppressed by shRNA, confirming that they protect by a mechanism that requires QPCT 
inhibition (Fig 3e, Supplementary Fig. 11e and 11f). Thus, even though these compounds 
also inhibited QPCT-like (Supplementary Fig. 11a) and we cannot exclude the possibility 
that at least some of the effects observed may be mediated by this QPCT isoenzyme, their 
effects on aggregation were QPCT-dependent, as the shRNA used did not target QPCT-like. 
Consistent with these data, SEN177 greatly reduced the early stages of mutant HTT 
oligomerisation, as it decreased the amounts of GFP-tagged monomeric HTT that were co-
immunoprecipitated by Flag-tagged HTT (Fig. 3f). The protective effect of these compounds 
was also confirmed in primary cortical neurons (Fig. 3g), with SEN177 and SEN817 
significantly reducing the percentage of neurons with Q80 aggregates.
QPCT modulates the levels of alpha B-crystallin
The effects of QPCT inhibition on HTT aggregation appeared to be independent of effects 
on protein clearance pathways targeting mutant huntingtin (autophagy and the ubiquitin-
proteasome system) (Supplementary Fig. 12), changes in mRNA or protein levels 
(Supplementary Fig. 13a and 13b), or secretion of the enzyme into the medium 
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(Supplementary Fig. 13c). QPCT is localized in the ER and secretory pathway and its 
knockdown, overexpression or inhibition seemed to have inconsistent and rather modest 
effects on different readouts of the ER stress response, measured by GRP78/BIP levels or 
phosphorylation of eIF2α, which did not correlate with its effect on aggregation 
(Supplementary Fig. 14). Our data also suggested that CREB (c-AMP response element 
binding protein) or ERK (extracellular signal-regulated kinase) signaling, recently reported 
to be activated upon QPCT inhibition 38 (Supplementary Fig. 15a and 15b), or JNK 
signaling (Supplementary Fig. 15c) were unlikely contributors to the effects we have 
observed.
QPCT overexpression or knockdown did not modulate levels of HSP70, the main inducible 
stress response chaperone (Supplementary Fig. 15d). We performed transcriptional profiling 
to assess changes in alternative molecular chaperones induced by SEN177 in the presence of 
mutant HTT, and observed upregulation of several small heat shock proteins (sHSPs) 
(HSPB6 with 1.6 fold-change; HSPB3 with 1.5 fold-change; HSPB7 with 1.5 fold-change; 
and notably, alpha B-crystallin which had >2.5 fold increase in transcript levels) 
(Supplementary Fig. 16a and Supplementary Data Set 3). We confirmed this induction at the 
protein level as well as with other QPCT inhibitors (Fig. 4a). Genetic inhibition of QPCT 
dramatically increased alpha B-crystallin protein and mRNA levels in the presence of 
HTT(Q74) (Fig. 4b and 4c and Supplementary Fig. 16b), while QPCT overexpression, 
which increased mutant HTT aggregation and toxicity (Fig. 2c and Supplementary Fig. 7a), 
reduced alpha B-crystallin levels (Supplementary Fig. 16c). QPCT also modestly modulated 
alpha B-crystallin levels in the absence of mutant HTT or in the presence of the non-
pathogenic Q23 (Supplementary Fig. 16b and 16c).
As a sHSP, alpha B-crystallin acts as a molecular chaperone and is a suppressor of 
polyglutamine toxicity in cells and in Drosophila 394041. As expected, overexpression of 
alpha B-crystallin lowered the number of HTT(Q74) aggregates, while QPCT inhibitors 
failed to reduce aggregation further (Fig. 4d and Supplementary Fig. 16d), suggesting that 
this increment in alpha B-crystallin was a major contributor to the protection afforded by 
QPCT inhibition.
QPCT inhibition protects fly and zebrafish HD models
We tested QPCT inhibitors in flies expressing Httex1Q46 in the eye and found a reduction 
in the number of aggregates (Fig. 5a). The compound with a greatest effect, SEN177, was 
able to also rescue the number of visible rhabdomeres and prevent neurodegeneration (Fig. 
5b).
A transgenic zebrafish expressing Htt exon 1 with 71Q fused to EGFP in the rod 
photoreceptors using the rhodopsin promoter has been established and validated as a model 
to study mutant huntingtin aggregation in vivo 42. Zebrafish have two homologs with 
putative glutaminyl-peptide cyclotransferase activity, QPCT and QPCTLA with 51% and 
47% protein identity with QPCT and QPCT-like respectively. In order to test the effect of 
pharmacologic inhibition of QPCT in this model, we first determined the maximum 
tolerated concentration for each of the three compounds tested in mammalian cells and 
subsequently treated HD larvae. SEN817 and SEN180 reduced total number of EGFP-
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aggregates in the retina (Fig. 6a), which correlated with a marked decrease in toxicity 
similar to the positive control, clonidine 42, assessed by a rescue in the total area of eye 
photoreceptors (Fig. 6b).
Although the three compounds were protective, their effectiveness varied between these 
models, which might be due to intrinsic properties of each system, SEN180 only mildly 
reduced aggregation in neurons and the effect of SEN817 was not significant in Drosophila. 
Although SEN177 had the highest in vitro activity and was able to efficiently reduce 
aggregates in mammalian cells, primary neurons and Drosophila, we found that this 
compound was tolerated at much higher concentrations than its analogs in zebrafish and 
therefore the bioavailability in this model is much lower, which could explain the lack of 
effect in this system. All together, we have identified a number of small molecules that 
through QPCT inhibition have beneficial effects on the treatment of HD in a variety of in 
vivo models.
Discussion
Our approach using a two-step screen, starting with an initial large-scale analysis in human 
cell models followed by a validation in Drosophila, has yielded a number of potentially 
druggable targets which may be suitable for HD. A variety of HT-RNAi screens have 
identified genetic suppressors of phenotypes mediated by mutant HTT N-terminal fragments 
in Drosophila, C. elegans and mammalian (mouse and human) cells 44454647. In most cases, 
aggregation was the primary readout, often measured with C-terminal GFP fusions. 
Differences in the nature of the previous screens (species, cellular context, huntingtin 
fragment length, length of the polyglutamine expansion, primary readout and differences in 
siRNA/shRNA sequences) complicates cross-screen comparisons. Also, virtually no screens 
in this area have examined their false negative rates due to inefficient knockdown. 
Additionally, the screen presented here was biased towards the druggable component of the 
human genome, and a further selection was made in the course of triaging towards specific 
protein target classes. This likely contributes to the relatively poor overlap of hits in the 
present and previous screens. A comparison with a screen performed in HEK293T cells to 
identify genetic suppressors of inducibly expressed mutant HTT exon 1 toxicity 46 revealed 
an overlap of only 4 genes (CPA1, GRIN2A, NR3C2 and USP21) when considering the top 
257 hits (Supplementary Data Set 1). However, matrix metalloproteases, identified in 
HEK293T cells as modulators of fragmentation and toxicity of N-terminal portions of 
mutant HTT 45 were also identified in our dataset, as well as PAK1, which we previously 
identified as a kinase promoting mutant HTT self-association and toxicity 25, thus validating 
the effectiveness of the screen.
Based on the reproducible and clear rescue that QPCT inhibition exerts on mutant HTT 
toxicity in cells and in Drosophila, we focused on this target. A catalytically inactive QPCT 
was not able to increase the number of aggregates, suggesting that pE modifications 
modulate the levels of aggregates in HD models. Although one obvious mechanism would 
involve cleavage of the polyglutamine tract followed by cyclation of an N-terminal pE 
residue that may change properties such as stability or hydrophobicity, which would account 
for its change in aggregation 22, our data suggest that the effect of QPCT on HTT may be 
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indirect. We found that modulation of aggregation by QPCT was not restricted to mutant 
HTT but it also affected aggregation of other aggregate-prone proteins and that QPCT 
influences the formation of mutant HTT oligomeric species. We observed an induction in 
several sHSPs, mostly alpha B-crystallin, suggesting that QPCT inhibition caused a stress 
response distinct from classical Hsp70 induction, which might be mediated by indirect 
substrates for pE modification. This molecular chaperone reduces aggregation of 
polyglutamine containing proteins 3941, alpha-synuclein 4841or amyloid-β peptide 4950, 
underscoring QPCT inhibition as an effective target for misfolded protein disorders. Since 
alpha B-crystallin is regulated at the transcriptional level while QPCT resides in the 
secretory pathway, inhibition of QPCT may activate a signalling response that enhance 
alpha B-crystallin transcription. Our data suggest that this is likely independent of an ER 
stress response or the involvement of ERK and CREB, which have been recently found 
phosphorylated upon QPCT inhibition 38, as well as other stress signalling pathways such as 
JNK. Further work will need to clarify the QPCT substrate mediating this effect. It is 
important to stress that the benefits of QPCT downregulation may not be restricted to alpha 
B-crystallin as an effector, as the upregulation of other related sHSPs may also contribute 
beneficially.
We identified and characterised a series of compounds that efficiently reduce mutant HTT 
aggregation in mammalian cell lines and also in primary mouse neurons, fly eye and in 
zebrafish. While the levels of rescue and significance obtained varied between compounds 
depending on the model used, this may be as a result of differences in absorption routes and 
bioavailability. Nevertheless, our data showed that pharmacologic inhibition of QPCT using 
this compound series can rescue HD phenotypes and provides proof-of-principle for QPCT 
as a potential therapeutic target for HD and possibly other related intracellular 
proteinopathies by modulating the formation of oligomeric forms, which have been 
proposed as the most toxic species in these diseases 78. Clearly, further work is required 
before considering that this will be clinically relevant, including likely additional drug 
development. Nevertheless, in a broader perspective, our data suggest that a discovery 
pipeline from druggable genome screen to drug development may be tractable for 
neurodegenerative diseases.
Online Methods
Assays for validation polyglutamine toxicity modifiers in Drosophila
Drosophila fly stocks—As a model of polyglutamine toxicity, flies that expressed a 
protein with 48 glutamines encoded by P{UAS-Q48.myc/flag}31 13 in eyes under control of 
the GMR-Gal4 driver P{GAL4-ninaE.GMR}12 51 (Q48) were used. Fly orthologs to the 
genes identified in the cell screen were selected by performing reciprocal BLASTP and 
cross checking with databases including http://www.ncbi.nlm.nih.gov/homologene, http://
www.genecards.org/, http://www.ensembl.org/index.html. The RNAi lines corresponding to 
the identified genes were obtained from Vienna Drosophila RNAi Center (VDRC, http://
stockcenter.vdrc.at/control/main).
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The following stocks were generous gifts: UAS-Q48.myc/flag from J.L. Marsh 13, UAS-
Httex1-Q46-eGFP from N. Perrimon 19. Fly lines that are not referenced here are 
documented in FlyBase (www.flybase.org).
All fly crosses and experiments were performed at 25°C.
Drosophila RNAi screen—Five virgins of genotype w; GMR-GAL4; UAS-Q48.myc/flag 
(Q48) were crossed to males carrying each UAS-RNAi (GD- and KK-RNAi collections, 
VDRC, http://stockcenter.vdrc.at/control/main). Genetic background was controlled by 
crossing w; GMR-GAL4; UAS-Q48.myc/flag females to w1118 males that share the same 
genetic background (VDRC stock number 60000 for the GD-RNAi lines and 60100 for the 
KK-RNAi lines). For Glutaminyl cyclase (CG32412) the GD-RNAi line 38277 and the KK-
RNAi line 106341 were used. For isoGlutaminyl cyclase (CG5976), the KK-RNAi line 
101533 was used. For GD-RNAi lines, degeneration was determined by scoring the eye 
depigmentation in the progeny of the above crosses 4 days after eclosion, assessing 
modification of polyglutamine loss-of-pigmentation and black necrotic-like spots. For KK-
RNAi lines, as their background leads to dark eye pigmentation (http://www.vdrc.at/rnai-
library/rnai-protocols), toxicity was assessed by scoring the presence or abscence of black 
necrotic-like spots in the eyes of 10-day old flies. Fisher’s exact test was performed to 
compare the numbers of necrotic-spot-containing flies in the KK-RNAi crosses with 
controls using an arbitrary p<0.005 as a statistical cut-off for significance. Eyes were imaged 
using a Nikon CoolPix 990 digital camera attached to a dissecting microscope.
EGFP expression levels assessed in Drosophila RNAi lines—Western blot 
analysis was performed using progeny of crosses between virgins of the genotype w; GMR-
GAL4; UASEGFP and males of each VDRC-RNAi line used or background control (VDRC 
stock number 60100). Fly heads were homogenized in Laemmli sample buffer. Rabbit 
polyclonal anti-GFP at 1:1000 (AbCam, Ab6556) and monoclonal anti-beta tubulin at 
1:10000 (Developmental Studies Hybridoma Bank) were used. Blots were scanned using 
Odyssey Fc Imaging System (LI-COR Biosciences). This validation was initially performed 
once on each suppressor, and subsequently RNAi lines showing an apparent reduction in 
EGFP levels were re-tested using the progeny of three independent crosses. Statistical 
analysis was performed by two-tailed paired t-test between the RNAi lines and the control 
line.
Pseudopupil assay—Analysis was performed as previously described 17. Virgins of 
genotype elav-GAL4C155; {GMR-HD.Q120}4.62/TM3 (elav-Gal4; GMR-HTT.Q120) 16 
were crossed with males carrying the RNAi construct for Glutaminyl cyclase (lines 
QCGD38277 or QCKK106341) or isoGlutaminyl cyclase (line isoQCKK101533) and compared to 
background control line.
To evaluate the effect of QPCT inhibitors, virgins of genotype yw; {GMRHD.Q120}2.4 
(GMR-HTT.Q120) were allowed to mate with w1118 control males for 48 hours on standard 
cornmeal food and then transferred on fly food containing the compounds.
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The number of rhabdomeres per ommatidium was scored in progeny of the above crosses at 
3 (GMR-Q120) or 4 (elav-Gal4; GMR-HTT.Q120) days post-eclosion. Statistical analysis 
was performed using one-tailed t-test on data from 3 or 4 independent experiments, each 
based on approximately 10 individuals for each genotype, scoring 15 ommatidia per eye. 
When compounds were tested, the analysis was done on females and males of each 
treatment separately.
Aggregate counting—Virgins of genotype w; GMR-GAL4; UAS-Httex1-Q46-eGFP 19 
were crossed with males of QPCT UAS-RNAi lines or from the background KK-RNAi 
control line, since all the background controls show similar aggregate scoring. Eye pictures 
of 18-day old progeny were taken using a Leica MZ16F microscope connected to a Leica 
DFC340FX digital camera. For each genotype, GFP punctae indicating aggregate formation 
was counted using ImageJ “Cell Counter” plugin in the eyes of 20 males, a pool of 5 males 
from four independent crosses. For compound testing, virgins of genotype w; GMR-GAL4; 
UAS-Httex1-Q46-eGFP were crossed with w1118 control males, and females of the progeny 
scored 15 days post-eclosion. The experiment was repeated at least three times and for each 
experiment at least 4 female eyes were scored. An unpaired one-tailed t-test was used to 
determine statistical significance for single comparisons between two groups using 
GraphPad Prism.
Compound treatment—Flies were reared on food (Instant Fly Food, Philip Harris, 
Ashby de la Zouch, UK) containing either QPCT inhibitor (50 μM) dissolved in DMSO or 
DMSO alone. The progeny were flipped every 2 days on fresh food containing the specific 
inhibitor or DMSO.
Bioinformatics Analysis
Ingenuity Pathways Analysis (Ingenuity® Systems, www.ingenuity.com) was used to 
analyze the distribution of siRNAs tested among the different protein classes as well as to 
determine the canonical pathways associated to the confirmed primary actives.
Assays for validation of polyglutamine toxicity and aggregation modifiers in human cell 
lines
Cell culture—HEK293 (Human Embryonic Kidney), HeLa (Human cervical carcinoma) 
cells and Atg5-deficient (Atg5-/-) mouse embryonic fibrolasts (MEFs) (gift from N. 
Mizushima) were grown in Dulbecco’s modified eagle medium supplemented with 10% 
FBS, 100 U/ml penicillin/streptomycin and 2 mM l-glutamine at 37°C in 5% CO2. 
UbG76V-GFP-expressing stable HeLa cell line (kind gift from N.P. Dantuma) was 
maintained in medium containing 0.5 mg/ml G418.
Isolation and culture of mouse primary cortical neurons—Primary cortical 
neurons were isolated from C57BL/6 mice (Jackson Laboratories) embryos at E16.5. 
Briefly, brains were harvested and placed in ice-cold PBS/glucose where the meninges were 
removed and the cerebral cortices were dissected. After mechanical dissociation using sterile 
micropipette tips, dissociated neurons were resuspended in PBS/glucose and collected by 
centrifugation. Viable cells were seeded on poly-ornithine-coated 12-multiwell plates. Cells 
Jimenez-Sanchez et al. Page 12
Nat Chem Biol. Author manuscript; available in PMC 2015 December 30.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
were cultured in Neurobasal medium supplemented with 2 mM glutamine, 200 mM B27 
supplement, and 1% Penicillin-Streptomycin at 37°C in a humidified incubator with 5% 
CO2. One half of the culture medium was changed every two days until treatment. After 5 
days of culturing in vitro, differentiated cortical neurons were infected with lentiviral 
particles bearing EGFP-Q80 and scramble or QPCT-directed shRNAs. Compounds were 
added 3 days after EGFP-Q80 viral infection and left for another 24h. When EGFP-Q80 was 
expressed together with shRNA, 5-6 days were needed before cultures were fixed in a 2% 
PFA-7.5% glucose solution.
DNA constructs—Human QPCT (NM_012413) plasmid was purchased from Origene 
(pCMV6-XL5-QPCT). A C-terminal Flag-tagged QPCT construct was generated by PCR 
amplification of QPCT cDNA from pCMV6-XL5-QPCT using primers overhanging HindIII 
and BgIII sites and insertion into the pCMV5-FLAG in HindIII and BamHI restriction sites, 
using standard restriction enzyme digestion and ligation procedures. QPCT(E201Q)-Flag 
was generated using QuickChange II Agilent Site-Directed mutagenesis kit with the 
following primers Fw 5′-CTTCTTTGATGGTCAAGAGGCTTTTCTTCACTGG-3′ and 
Rev 5′-CCAGTGAAGAAAA GCCTCTTGACCATCAAAGAAG-3'. pcDNA or pCMV5-
Flag empty vectors were used as mock controls for pCMV6-XL5-QPCT or QPCT-Flag 
respectively.
Constructs expressing the first exon of the Htt gene carrying 74 polyglutamines expressed 
from pEGFP-C1 (Clontech) (EGFP-HTTQ74) or pHM6 (Roche Diagnostics) (HAHTTQ74), 
or with only 23 polyglutamines (EGFP-HTTQ23), were described previously 52. pEGFP-
N1-Q57 and pEGFP-N1-Q81 23 and pEGFP-C1-A37 24 have been previously described. 
Mutant HTT(1-588)-Flag was provided by MR Hayden and mutant HTT(1-548)GFP 
generated by S. Luo 25. 3xFlag-CRYAB construct has been previously described 53. The 
pGL3-BIP/GRP78-luciferase construct was kindly provided by M. Renna 54
Reagents—Chemical compounds used in cell culture were the autophagy inhibitors 
Bafilomycin A1 (400nM, DMSO; 4 hours; Millipore) and 3MA (10 mM, 16 hours; 
SIGMA), staurosporine (3 μM) and the proteasome inhibitor MG132 (10 μM). PBD150 was 
synthesized as described in 26.
Transfection—Cells were transfected in 6-well plates with 0.5-1.5 μg of DNA and 5 μl of 
Lipofectamine (Invitrogen) or TransIT-2020 (Mirus) per well for 4 hours in Optimem 
(GIBCO-BRL) and then incubated in full media for 48 hours. Gene knockdown experiments 
were performed using ON-TARGETplus SMARTpool siRNA (Dharmacon) for human 
QPCT, consisting on 4 siRNAs with the following sequences: 
CUAUGGGUCUCGACACUUA; GUACCGGUCUUUCUCAAAU; 
CCUUAAAGACUGUUUCAGA; GGAACUUGCUCGUGCCUUA, and which do not 
target the QPCT like sequence. For siRNA treatment, a single transfection protocol using 
50nM siRNA for 48 h or a double transfection protocol which consisted on a first 50 nM 
siRNA transfection followed by a second 50 nM siRNA transfection after 48 hours.
Western blotting—Cells were washed once in PBS and harvested on lysis buffer (20 mM 
Tris-HCl pH 6.8, 137nM NaCl, 1 mM EGTA, 1% Triton X-100, 10% glycerol, 1x Roche 
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complete mini protease inhibitor). Equal loading was obtained by protein concentration 
determination using a Bio-Rad assay followed by resuspension and boiling in Laemli buffer. 
Samples were subjected to 12% SDS-PAGE and transferred to PVDF membrane 
(Immobilion-P, GE Healthcare). Blots were proved with primary antibody: anti-LC3 
(1:2000; Novus Biologicals, NB100-2220), anti-Hsp70 (1:1000; Enzo SPA810), anti-
CRYAB (1:1000; Cell signalling 8851), anti-actin (1:2000; Sigma, A2066), anti-α-tubulin 
(1:4000; T9026, Sigma), anti-Flag epitope (1:2000; SIGMA, F7425), anti-GFP (1:1000; 
Clontech, Living colours, polyclonal), eIF2α (1:1000, Abcam 5369) and phospho-S51-
eIF2α_(1:1000, Abcam 32157), GRP78 (1:1000, Abcam 21685), anti-phospho-ERK 
(1:1000, Cell signalling, 9101), anti-ERK (1:1000, Cell signalling, 9102), anti-phospho-
CREB (S133) (1:1000, Cell signalling 9191), anti-CREB 86B10 (1:1000, Cell signalling, 
9104), anti-phospho-JNK (1:1000, Cell signalling, 9255), anti-JNK (1:1000, Cell signalling, 
9252). The appropriate anti-mouse or anti-rabbit secondary antibodies were used and 
visualized using an ECL detection kit (Amersham) or LI-COR Biosciences infrared imager 
(Odyssey).
Caspase 3/7 activity assay—Cells were seeded in a 96-well plate 24h prior to the assay 
and 1 μM staurosporine or DMSO was added for the last 8h. Caspase 3/7 activity was 
measured by using a luminogenic caspase 3/7 substrate (Caspase 3/7-Glo Assay, Promega) 
following manufacturer protocols in a Glomax luminometer (Promega). Protein 
concentration was determined in each cell lysate and caspase 3/7 activity was normalized to 
protein levels.
Co-inmunoprecipitation assays—Assays were performed as previously described 25, 
where HTT(1-588)Flag(Q138) and HTT(1-548)GFP(Q138) were expressed in HeLa cells 
together with QPCT plasmid for 48h, or treated with 25 μM SEN177 for 24h. Cells were 
lysed in buffer B containing 10 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA pH8, 1% 
triton and 1x Roche complete mini protease inhibitor for 20 min on ice, followed by 
centrifugation at 13000 rpm for 10 min. Five hundred micrograms total protein were 
incubated with primary anti-Flag M2 (Sigma) or anti-GFP (Clontech, Living colours, 
polyclonal) at 5 μg/ml overnight at 4°C. Protein G Dynabeads (LifeTechnologies) were 
added and incubated for further 2 h. Beads were washed 3 times with buffer B and eluted 
using 0.1 M glycine pH 2.5M followed by boiling in laemli buffer. Samples were subjected 
to western blot and visualized using LICOR. A fraction of the total lysates was run 
simultaneously.
Reverse-transcriptase PCR analysis—Total RNA was isolated from cell pellets using 
Trizol Reagent (Invitrogen), treated with DNase I, and cDNA synthesis was performed by 
SuperScript III First-Strand Synthesis System (Invitrogen). Standard conditions were used 
for cDNA amplification and PCR products were analyzed by agarose gel electrophoresis and 
ethidium bromide staining or quantitated with real-time PCR. For real-time PCR analysis, 
the reaction mixture containing cDNA template, primers, and SYBR Green PCR Master 
Mix (Invitrogen) was run in a 7900 Fast Real-time PCR System (Applied Bio-systems, 
Carlsbad, CA). Fold changes on mRNA levels were determined by standard curve and after 
normalization to internal control β-actin RNA levels. Primer sequences used in this study 
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are: QPCT, 5′-CATGGCATGGATTTATTGG-3′ and 5′- GACGGTATCAGATCAAAC-3′; 
QPCT-like, 5′- CAGCGTCTCTGGAGCACTTA-3′ and 5′- 
GCCTCCAGGAACTTTCTGACT-3; GFP 5′- ACGTAAACGGCCACAAGTTC-3′ and 5′- 
TTCAGGGTCAGCTTGCCGTA-3′; actin, 5′-AGAAAATCTGGCCCACACC-3′ and 5′-
GGGGTGTTGAAGGTCTCAAA-3′; CRYAB, 5′- TCTTGAGCTCAGTGAGTACTGG-3′ 
and 5′-AGCTCACCAGCAGTTCATGG-3′; and mouse QPCT, 5′-
CGACTTGAGCCAATTGCTGA-3′ and 5′-CTTCCGGGTTAAGAGTGCTG-3′.
mRNA isolation from mouse brain—All mouse experiments were performed under 
appropriate UK Home Office licences and following institutional procedures. We analyzed 
samples from N171 mutant HD mice and wild-type littermate controls at 20 week. mRNA 
was extracted from brains homogenized in Trizol (Invitrogen) using an Ultra torax 
homogenizer.
Lentivirus infection—shRNA containing pLKO.1 vectors targeting both mouse and 
human QPCT (TRCN032432) were obtained from The RNAi Consortium (TRC) and 
scramble shRNA vector was generated in D. Sabatinit’s laboratory (Addgene, plasmid 
1864). Lentiviral plasmids to express Q80-GFP were kindly provided by J. Uney 55. 
Lentiviral particles were produced and transduced following The RNAi Consortium 
protocols.
Cell toxicity and aggregation assays—Cells were fixed for 7 minutes in 4% 
paraformaldehyde (PFA). For EGFP-tagged constructs, slides were mounted in Citifluor 
(Citifluor, Ltd.) containing 4′,6-diamidino-2-phenylindole (DAPI; 3 μg/ml; Sigma) and 
visualized using an Eclipse E600 fluorescence microscope (plan-apo 60x/1.4 oil immersion 
lens) (Nikon). For detection of HA-tagged constructs, inmunofluorescence with an anti-HA 
(Covance laboratories 1:500) and anti-mouse Alexa488 secondary antibody (Invitrogen, 
1:1000) was performed followed by mounting in Citiflour-DAPI. We assessed the 
percentage of transfected cells (EGFP- or HA-positive cells) with at least one aggregate per 
cell. Apoptotic cell death was determined by assessing the nuclear morphology (nuclei 
fragmented or condensed) in transfected cells. Slides were blinded and at least 200 
transfected cells per slide were scored; each individual experiment was performed in 
triplicate.
Detection of nascent protein synthesis—Protein synthesis was assessed by metabolic 
incorporation of AHA (L-azidohomoalanine) into cells transfected with EGFP-HTT(Q23). 
Briefly, 12 hours after HeLa cells transfection, media was washed and replaced with L-
methionine/L-cysteine free medium and treated with DMSO or SEN177 (50 uM) for 1h 
prior to addition of AHA (L-azidohomoalanine) to the media and collection of cells every 2 
hours. Labelled protein was detected by western blot after performing Click-IT protein 
detection assay (Life Technologies) using biotin, following manufacturer protocols.
Luciferase reporter assay—Cells were transfected with 1 μg of GRP78-luciferase 
(firefly) reporter construct and 50 ng of renilla-luciferase (pRL-TK) as an internal 
transfection efficiency control. Cells were collected in Passive lysis buffer and luciferase 
activity was measured using the Dual-luciferase Reporter Assay System (Promega) 
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following manufacturer’s protocol in a Glomax Luminometer (Promega). GRP78-luciferase 
relative activity was calculated relative to the renilla-luciferase transfection efficiency 
control activity for each sample; experiments were performed in triplicate.
Statistical analysis—Quantification of immunoblots was performed by densitometric 
analysis using the Image J software or the LI-COR Biosciences infrared imager software and 
normalized to loading control (actin or tubulin, as indicated). The p-values were determined 
by two-tailed Student’s t-test.
Aggregates were counted in at least 200 cells per slide (with the observer blinded to their 
identity), and percentage was calculated relative to control conditions. p-values were 
determined by unpaired two-tailed Student’s t-test.
All experiments were done at least three times in triplicate and a representative blot or graph 
from a triplicate experiment is shown unless indicated.
Heat shock proteins and chaperones PCR array—The Human Heat Shock Proteins 
and Chaperones RT2 Profiler PCR Array (SABiosciences, Frederick, MD) was used to 
study the expression profile of 84 heat shock proteins according to the manufacturer’s 
procedure. Briefly, total RNA was extracted from cells transfected with HTT(Q74)GFP 
treated with DMSO or 25 uM of SEN177 inhibitor for 24h, using Trizol (Invitrogen) and 
further purified using RNeasy mini kit with oncolumn DNAse digest (Qiagen), cDNA was 
then synthesized using an RT2 First strand kit (SABiosciences) and real-time PCR was 
performed using 7900HT fast real time PCR system (Applied iosciences). Data were 
analysed with RT2 profiler PCR array data analysis software version 3.5.
Assays for validation of polyglutamine aggregation modifiers in zebrafish
Maintenance of zebrafish stocks and collection of embryos—All zebrafish 
husbandry and experiments were performed in accordance with UK legislation under a 
licence granted by the Home Office and with local ethical approval. Zebrafish were reared 
under standard conditions (Westerfield et al, 2005) on a 14 h light/10 h dark cycle. Embryos 
were collected from natural spawnings, staged according to the established criteria 56 and 
reared in embryo medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM Mg2SO4, 
5 mM HEPES).
Determination of the maximum-tolerated concentration of compounds in 
larval zebrafish—Compound exposure experiments were performed on wild-type larvae 
(TL strain) from 2 to 3 days post-fertilization (d.p.f.). Concentration response assays were 
performed over log intervals, from 100 nM to 1 mM, to determine the maximum non-toxic 
concentration (MTC) for subsequent aggregate analysis assays (n=10 larvae per 
concentration). Compound exposure experiments were performed in the dark at 28.5 °C.
Measuring aggregate number and rhodopsin protein levels in transgenic HD 
zebrafish—Aggregate counting and analysis of rod photoreceptor degeneration 
(photoreceptor number) was performed using heterozygous larvae from Tg (rho:EGFP-
HTT71Q)cu5 zebrafish 42 (hereafter referred to as transgenic HD zebrafish). Embryos from 
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outcrossed transgenic HD zebrafish were raised in 0.2 mM 1-phenyl-2-thiourea (PTU) from 
1 to 3 d.p.f. to inhibit pigment formation, screened for transgene expression using EGFP 
fluorescence, and then washed twice in the embryo medium to remove PTU. From 3 to 9 
d.p.f., transgenic HD zebrafish larvae were dark-reared in embryo medium alone or embryo 
medium contain containing either DMSO, 1mM SEN177, 100 μM SEN180 or 100 μM 
SEN817. Embryo medium and compounds were replenished daily. Larvae were 
anaesthetized by immersion in 0.2 mg/ml 3-amino benzoic acid ethyl ester (MS222), then 
fixed for aggregate counting at 7 d.p.f. or for photoreceptor analysis at 9 d.p.f. Anaesthetised 
larvae were fixed using 4% paraformaldehyde (PFA) in PBS at 4 °C. Larvae were washed 
briefly in PBS, allowed to equilibrate in 30% sucrose in PBS then embedded in OCT 
medium (Tissue-Tek) and frozen on dry ice for subsequent cryosectioning. Sections were 
cut at 10 μm thickness using a cryostat (Bright Instruments). For aggregate counting, 
sections were mounted in 50% glycerol in PBS and the total number of GFP-positive 
aggregates were counted over 100 μm of the central retina, either side of the optic nerve 
head and mean values were calculated (n = 5 fish (10 eyes)) for each treatment group. For 
quantification of photoreceptor number, the GFP-positive area of the central retina was 
quantified using image thresholding and area analysis in ImageJ (n ≥ 5 fish (10 eyes) for 
each treatment group). To demonstrate that loss of GFP corresponds to loss of 
photoreceptors, sections were stained with anti-rhodopsin (1D1) antibody (a kind gift from 
Paul Linser, University of Florida, FL 57 and mounted using VectaShield hard set mounting 
medium (Vector Laboratories). Sections were viewed and representative images acquired 
using a GX Optical LED fluorescent microscope, GXCAM3.3 digital camera and GX 
Capture software.
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Figure 1. Downregulation of QPCT in flies rescues HD toxicity
a. The eye phenotype of flies that express Q48 crossed to w1118 (VDRC stock number 
60000) is rescued upon downregulation of Drosophila Glutaminyl cyclase (QCGD38277, 
VDRC GD-RNAi line 38277). Representative images of eye pigmentation rescue are shown. 
F=female; M=male.
b. Downregulation of QPCT fly orthologs QC and isoQC using KK-RNAi lines (lines 
QCKK106341 and isoQCKK101533) reduced the number of black necrotic-like spots on Q48 
flies (see Supplementary Fig.5a for quantification). Fisher’s exact test was applied for 
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statistical comparison between control and test genotypes. Females: isoQCKK101533 p=2.42 
E-14; QCKK106341 p= 3.05 E-12; males: isoQCKK101533 p=3.53 E-0.8; QCKK106341 p= 1.72 
E-0.9
c. Loss of rhabdomeres due to expression of expanded huntingtin exon1 (elav-Gal4; 
GMRHTT.Q120) in the eye was significantly rescued upon downregulation of QPCT fly 
orthologues QC or isoQC (GD- or KK-RNAi lines as indicated). Graph shows the mean ± 
SEM of the average number of rhabdomeres per eye from 4 independent experiments; one-
tailed paired t-test was used to test significance.
d. The number of aggregates in the eyes of flies expressing expanded huntingtin HTTex1-
Q46-eGFP using GMR-GAL4 was reduced by downregulating QPCT fly orthologs QC and 
isoQC (RNAi lines isoQCKK101533, QCKK10634, QCGD38277). Graph shows mean ± SEM of 
the number of aggregates from 4 independent crosses for each genotype with control levels 
set at 100%. One-tailed paired t-test was used for comparison between control and test 
genotypes (n = 4).
In all panels, * p<0.05, ** p<0.01 and *** p<0.001. Scale bars represent 200 μm.
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Figure 2. QPCT modulates HTT toxicity and aggregation in mammalian cell lines and primary 
neurons
a. The percentage of cells with apoptotic nuclei or HTT(Q74) aggregates is reduced in 
HEK293 cells transiently expressing EGFP-HTT(Q74) and treated with QPCT siRNA. 
Representative images are shown in supplementary figure 6a.
b. QPCT shRNA significantly reduced the number of aggregates in mouse primary cortical 
neurons expressing Q80-EGFP. Scale bar represents 10 μm. The mean of 3 independent 
experiments in triplicate is represented in the graph. Significance was analysed by two-tailed 
paired Student’s t-test.
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c,d. Overexpression of QPCT (pCMV6-QPCT) together with EGFP-HTT(Q74) in HeLa 
cells for 48h increased the percentage of cells with apoptotic nuclear morphology and 
aggregates (c), this effect is not observed with a catalytically inactive QPCT 
(QPCT(E201Q)-Flag) (d).
e. The percentage of HeLa cells expressing EGFP-HTT(Q74), EGFP-Q57 or EGFP-Q81 
with aggregates is enhanced upon QPCT-Flag overexpression for 48 h.
f. QPCT siRNA reduces the percentage EGFP-Q81 or EGFP-A37 with aggregates in 
HEK293.
g. Overexpression of QPCT enhanced the amount of mutant HTT(1-548)-Flag co-
immunoprecipitating with HTT(1-588)-GFP. Levels of Flag-HTT(1-588) co-
immunoprecipitated relative to total lysates from 5 independent experiments are represented 
in the graph. Data were analyzed by two-tailed paired Student’s t-test (n= 5 experiments). 
Full blot images are shown in Supplementary Fig. 17a.
In all panels, unless indicated, graphs show mean values with control conditions set to 100 
and error bars represent standard deviation from a triplicate experiment representative of at 
least three independent experiments. Statistical analyses were performed by two-tailed 
unpaired Student’s t-test: ***p<0.001, **p<0.01; *p<0.05; NS, not significant
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Figure 3. Design of QPCT inhibitors that reduce mutant HTT aggregation
a. Chemical structure of compounds designed to inhibit QPCT activity. Table indicating the 
activity and in vitro ADME properties of the compounds is shown in supplementary fig. 
11a.
b,c. Treatment of HeLa cells expressing EGFP-HTT(Q74) with SEN177, 817 and 180 (50 
μM) for 24h reduced the percentage of cells with aggregates (b) and apoptotic nuclei (c).
d. SEN177 reduces the percentage of HEK293 cells with EGFP-HTT(Q74) or EGFP-A37 
aggregates in a concentration-dependent manner.
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e. SEN177 does not further reduce the percentage of EGFP-HTT(Q74) aggregates in QPCT 
shRNA transfected cells.
f. SEN177 reduces the amount of HTT(1-588)-GFP co-immunoprecipitating with 
HTT(1-548)-Flag in HeLa cells (25 μM SEN177). The amount of GFP-HTT(1-548) 
immunoprecipitated relative to total lysates was quantifiedand the average of 5 independent 
experiments is shown in the graph. Data were analyzed by two-tailed paired Student’s t-test 
(n= 5 experiments). Full blot images are shown in Supplementary information 17b.
g. Primary neurons expressing EGFP-Q80 for 3 days were treated with 50 μM of indicated 
compounds for further 24h.
In all panels, unless indicated, graphs show mean values with control conditions set to 100 
and error bars represent standard deviation from a triplicate experiment representative of at 
least three independent experiments. Statistical analyses were performed by two-tailed 
unpaired Student’s t-test: ***p<0.001, **p<0.01; *p<0.05; NS, not significant.
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Figure 4. QPCT inhibition induces alpha B-crystallin levels
a. Alpha B-crystallin (Cryab) protein levels were increased in cells transfected with 
HTT(Q74)GFP and treated with the indicated compounds at 25 μM for 24 h. Full blot 
images are shown in Supplementary information 17c.
b,c. Knockdown of QPCT for 24 h followed by transfection with HTT(Q74)GFP for another 
24h increased protein (b) and mRNA (c) levels of alpha B-crystallin. Fold change in mRNA 
of QPCT or alpha B-crystallin is represented in the graph with error bars representing 
standard deviation. The mean of three independent experiments in triplicate was normalized 
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to 1 and significance was calculated by one sample t-test. Full blot images are shown in 
Supplementary information 17d.
d. Overexpression of alpha B-crystallin (CRYAB-Flag) reduced the percentage of cells with 
HTT(Q74)GFP aggregates. SEN817 decreased aggregation when added at 25 μM for 24h in 
control but not CRYAB-expressing cells. In all panels, unless indicated, graphs show mean 
values with control conditions set to 100 or 1, and error bars represent standard deviation 
from a triplicate experiment representative of at least three independent experiments. 
Statistical analyses were performed by two-tailed unpaired Student’s t-test: **p<0.01; 
*p<0.05; NS, not significant.
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Figure 5. Pharmacologic inhibition of QPCT in fly
a. Flies that expressed HTTex1-Q46-eGFP in the eye have fewer aggregates after treatment 
with 50 μM of indicated compounds . Graph represents mean ± SEM from 4 independent 
crosses for each compound. Statistical analyses were performed by one-tailed unpaired 
Student’s t-test. Scale bars represent 200 μm.
b. Flies expressing HTTEx1-Q120 (GMR-HTT.Q120) show more rhabdomeres after 
treatment with SEN177 (50 μM). Graph represents the average number of rhabdomeres per 
eye ±SEM from 3 independent experiments with females and males counted separately, each 
based on approximately 10 individuals per datapoint, scoring 15 ommatidia from each 
individual. Statistical analysis was performed using one-tailed paired Student’s t-test.
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Figure 6. Pharmacologic inhibition of QPCT in zebrafish
a. Representative sections through the central retina of transgenic HD zebrafish at 7 d.p.f. 
treated with DMSO, SEN177 (1 mM), SEN817 (100 μM) or SEN180 (100 μM) showing 
aggregates (arrow) within the rod photoreceptors. Scale bar represents 10 μm. Treatment 
with QPCT inhibitors resulted in reduction in aggregates (Student’s t-test) for SEN187 and 
SEN810.
b. Representative sections through the central retina of transgenic HD zebrafish at 9 d.p.f. 
treated with DMSO, SEN177 (1 mM), SEN817 (100 μM) or SEN180 (100 μM). To 
demonstrate that loss of GFP corresponds to loss of photoreceptors, sections were stained 
with anti-rhodopsin (1D1) antibody (red). GFP labels the whole rod photoreceptor, whereas 
rhodopsin is present in the rod outer segment. Merged images show co-localisation of GFP 
the rhodopsin (red). Photoreceptor degeneration is ameliorated by SEN817 and SEN180. 
Scale bars, 10 μm.
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In all panels, **p<0.01; *p<0.05; NS, not significant.
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